229 related articles for article (PubMed ID: 32679279)
1. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.
Georgakopoulos JR; Mufti A; Vender R; Yeung J
J Am Acad Dermatol; 2020 Oct; 83(4):1212-1214. PubMed ID: 32679279
[No Abstract] [Full Text] [Related]
2. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
Gisondi P; Facheris P; Dapavo P; Piaserico S; Conti A; Naldi L; Cazzaniga S; Malagoli P; Costanzo A
Br J Dermatol; 2020 Aug; 183(2):373-374. PubMed ID: 32343839
[No Abstract] [Full Text] [Related]
3. Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.
Holcomb ZE; Santillan MR; Morss-Walton PC; Salian P; Her MJ; Giannotti NM; Kimball AB; Porter ML
J Am Acad Dermatol; 2020 Oct; 83(4):1215-1218. PubMed ID: 32622141
[No Abstract] [Full Text] [Related]
4. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Wan MT; Shin DB; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2020 Aug; 83(2):677-679. PubMed ID: 32416207
[No Abstract] [Full Text] [Related]
5. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.
Gisondi P; Zaza G; Del Giglio M; Rossi M; Iacono V; Girolomoni G
J Am Acad Dermatol; 2020 Jul; 83(1):285-287. PubMed ID: 32330632
[No Abstract] [Full Text] [Related]
6. COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy.
Carugno A; Gambini DM; Raponi F; Vezzoli P; Locatelli AGC; Di Mercurio M; Robustelli Test E; Sena P
J Am Acad Dermatol; 2020 Jul; 83(1):292-294. PubMed ID: 32387660
[No Abstract] [Full Text] [Related]
7. The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Syed MN; Shin DB; Wan MT; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2020 Nov; 83(5):1523-1526. PubMed ID: 32622891
[No Abstract] [Full Text] [Related]
8. Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?
Megna M; Fabbrocini G; Marasca C
Int J Dermatol; 2020 Sep; 59(9):1144-1145. PubMed ID: 32710548
[No Abstract] [Full Text] [Related]
9. Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
Mahil SK; Yiu ZZN; Mason KJ; Dand N; Coker B; Wall D; Fletcher G; Bosma A; Capon F; Iversen L; Langan SM; Di Meglio P; Musters AH; Prieto-Merino D; Tsakok T; Warren RB; Flohr C; Spuls PI; Griffiths CEM; Barker J; Irvine AD; Smith CH;
Br J Dermatol; 2020 Aug; 183(2):404-406. PubMed ID: 32348554
[No Abstract] [Full Text] [Related]
10. Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto.
Georgakopoulos JR; Yeung J
J Cutan Med Surg; 2020; 24(4):424-425. PubMed ID: 32475151
[No Abstract] [Full Text] [Related]
11. Are children less susceptible to COVID-19?
Lee PI; Hu YL; Chen PY; Huang YC; Hsueh PR
J Microbiol Immunol Infect; 2020 Jun; 53(3):371-372. PubMed ID: 32147409
[No Abstract] [Full Text] [Related]
12. Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.
Georgakopoulos JR; Vender R; Yeung J
J Cutan Med Surg; 2020; 24(4):418-419. PubMed ID: 32396018
[No Abstract] [Full Text] [Related]
13. Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.
Facheris P; Valenti M; Pavia G; Gargiulo L; Narcisi A; Costanzo A; Borroni RG
Int J Dermatol; 2020 Aug; 59(8):e267-e268. PubMed ID: 32557532
[No Abstract] [Full Text] [Related]
14. [Not Available].
Nau JY
Rev Med Suisse; 2020 Jun; 16(696):1174-1175. PubMed ID: 32496708
[No Abstract] [Full Text] [Related]
15. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.
Ghazawi FM; Lim M; Dutz JP; Kirchhof MG
Int J Dermatol; 2020 Sep; 59(9):1043-1056. PubMed ID: 32621284
[TBL] [Abstract][Full Text] [Related]
16. [COVID-19 and the 3 "P": Pandemic, Pediatrics and impact in the Country].
Torres Torretti JP; O'Ryan Gallardo M
Rev Chil Pediatr; 2020 Jun; 91(3):322-323. PubMed ID: 32730510
[No Abstract] [Full Text] [Related]
17. Development of child immunity in the context of COVID-19 pandemic.
Kloc M; Ghobrial RM; Kuchar E; Lewicki S; Kubiak JZ
Clin Immunol; 2020 Aug; 217():108510. PubMed ID: 32544611
[TBL] [Abstract][Full Text] [Related]
18. Anti-glomerular basement membrane disease during the COVID-19 pandemic.
Prendecki M; Clarke C; Cairns T; Cook T; Roufosse C; Thomas D; Willicombe M; Pusey CD; McAdoo SP
Kidney Int; 2020 Sep; 98(3):780-781. PubMed ID: 32599088
[No Abstract] [Full Text] [Related]
19. A Laboratory Risk Assessment during the Coronavirus (COVID-19) Pandemic.
Nichols JH; Rauch CA
J Appl Lab Med; 2020 Jul; 5(4):808-811. PubMed ID: 32529229
[No Abstract] [Full Text] [Related]
20. A Call for a Three-Tiered Pandemic Public Health Strategy in Context of SARS-CoV-2.
Hanley BP; Keen S; Church G
Rejuvenation Res; 2020 Aug; 23(4):281-283. PubMed ID: 32539623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
